Holen Sie sich die Stockscreener-App
0.8116
0.28%
0.0021
Schlusskurs vom Vortag:
$0.8095
Offen:
$0.8199
24-Stunden-Volumen:
436.77K
Relative Volume:
0.42
Marktkapitalisierung:
$97.07M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-25.91M
KGV:
-3.2245
EPS:
-0.2517
Netto-Cashflow:
$-22.73M
1W Leistung:
+4.75%
1M Leistung:
-21.18%
6M Leistung:
-21.94%
1J Leistung:
+94.02%
1-Tages-Spanne:
$0.81
$0.83
1-Wochen-Bereich:
$0.77
$0.8395
52-Wochen-Spanne:
$0.3258
$1.51
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Firmenname
Oncolytics Biotech Inc
Sektor
Branche
Telefon
(403) 670-7377
Adresse
SUITE 325, 4350 EXECUTIVE DRIVE, SAN DIEGO, AB
Compare ONCY vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.8133 | 96.62M | 0 | -25.91M | -22.73M | -0.2517 |
VRTX
Vertex Pharmaceuticals Inc
|
437.20 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.92 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.45 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.78 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.25 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-13 | Eingeleitet | Lake Street | Buy |
| 2022-10-06 | Eingeleitet | Maxim Group | Buy |
| 2021-02-17 | Eingeleitet | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Aktie (ONCY) Neueste Nachrichten
From Ambrx to Oncolytics: Why Jared Kelly Believes the Market May Be Missing the Bigger Oncology Story - Times Argus
H.C. Wainwright reiterates Oncolytics Biotech stock rating at buy By Investing.com - Investing.com Nigeria
ONCY Reiterated by HC Wainwright & Co. -- Price Target Maintained at $10 - GuruFocus
Oncolytics (ONCY) to Present Key Trial Data at 2026 ASCO Annual Meeting - GuruFocus
Oncolytics Biotech Reports New Clinical Data on Pelareorep for Pancreatic and Gastrointestinal Cancers in 2026 8-K Filing - Minichart
Oncolytics Biotech Inc - Baystreet.ca
Stocks in play: Oncolytics Biotech Inc - Barchart.com
Oncolytics Biotech (Nasdaq: ONCY) shows pelareorep immune activation data at ASCO 2026 - Stock Titan
New cancer immunotherapy linked to tumor volume drops at ASCO - Stock Titan
Stocks In Play - Baystreet.ca
ONCY Stock Price, Quote & Chart | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) - ChartMill
Oncolytics Biotech® Announces Receipt of Nasdaq Notification Let - GuruFocus
ONCY: Aligns with FDA on pivotal trial for Pelareorep in anal cancer - MSN
ONCY: Aligns with FDA on Pivotal Trial for Pelareorep in Anal Cancer - Yahoo Finance
ONCY Technical Analysis | Trend, Signals & Chart Patterns | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) - ChartMill
ONCY Should I Buy - Intellectia AI
Oncolytics Biotech Inc.Common Stock (NQ: ONCY - FinancialContent
Oncolytics Biotech stock (CA6823101073): Q1 loss deepens and going concern warning puts focus on cas - AD HOC NEWS
Oncolytics Biotech (ONCY) doubles Q1 loss and warns on going concern - Stock Titan
"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies - GlobeNewswire Inc.
Oncolytics Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Oncolytics Biotech stock (CA6823101073): Q4 earnings miss and upcoming report - AD HOC NEWS
TradingKey - TradingKey
Oncolytics Biotech (ONCY) Eps Diluted (TTM) - Zacks Investment Research
Lobbying Update: $35,000 of ONCOLYTICS BIOTECH INC. lobbying was just disclosed - Quiver Quantitative
ONCY: Oncolytics BiotechInteractive Chart - Zacks Investment Research
Penny Stock Oncolytics Biotech Says Colorecatal Cancer Drug's Durability Tops Historical Benchmarks - MSN
Oncolytics Biotech’s Pelareorep Data Reshapes Colorectal Cancer And Investor Outlook - Sahm
Oncolytics Biotech Reports Data in Colorectal Cancer Study - IPO Edge
Oncolytics Biotech (ONCY) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum - Quantisnow
Lake Street Maintains Oncolytics Biotech(ONCY.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Oncolytics Biotech Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer, Pursues Accelerated FDA Approval for Pelareorep Therapy 7 - Minichart
Oncolytics Says Colorectal Cancer Drug Outperforms BenchmarksOncolytics Biotech (NASDAQ:ONCY) - Benzinga
Oncolytics Biotech Highlights Strong Pelareorep Data in Colorectal Cancer - TipRanks
Oncolytics Reports 19.5-Month Median Duration of Response in 2L KRAS-Mutant MSS mCRC - TradingView
Oncolytics Biotech® Reports Durable Responses In Second-Line Ras-Mutant Mss Colorectal Cancer - TradingView
A colorectal cancer study hit 19.5-month response duration as FDA talks start - Stock Titan
Durable mCRC responses spur FDA talks for Oncolytics Biotech (NASDAQ: ONCY) - Stock Titan
Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer - Yahoo Finance
CEO Chat with Jared Kelly, CEO of Oncolytics Biotech - Zacks Small Cap Research
$207B Market Shift: The Race for Fast Track Approval in Oncology - Quantisnow
Oncolytics Biotech Inc. (NASDAQ:ONCY) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Oncolytics Biotech (ONCY) and Agilon Health (AGL) - The Globe and Mail
Oncolytics aligns with FDA on pivotal trial design for anal cancer By Investing.com - Investing.com South Africa
Oncolytics aligns with FDA on pivotal trial design for anal cancer - Investing.com UK
Oncolytics Biotech Aligns With FDA on Study Design for Pelareorep in Anal Cancer - marketscreener.com
Oncolytics (ONCY) Secures FDA Agreement on Pivotal Study Design - GuruFocus
Oncolytics Biotech Inc announces alignment with FDA on pivotal anal cancer study - marketscreener.com
Oncolytics Biotech Aligns with FDA on Pelareorep Trial - TipRanks
Oncolytics Biotech Aligns with FDA on Pivotal Study for Anal Cancer Immunotherapy Approval - Minichart
Finanzdaten der Oncolytics Biotech Inc-Aktie (ONCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Oncolytics Biotech Inc-Aktie (ONCY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kelly Jared | Chief Executive Officer |
Mar 12 '26 |
Buy |
0.96 |
5,050 |
4,848 |
114,050 |
| Kelly Jared | Chief Executive Officer |
Feb 12 '26 |
Buy |
0.84 |
29,500 |
24,839 |
109,000 |
| Kelly Jared | Chief Executive Officer |
Feb 11 '26 |
Buy |
0.84 |
5,600 |
4,682 |
79,500 |
| Look Kirk | Chief Financial Officer |
Feb 12 '26 |
Buy |
0.84 |
12,000 |
10,104 |
287,515 |
| Pisano Wayne | Director |
Feb 12 '26 |
Buy |
0.84 |
30,000 |
25,338 |
492,414 |
| Heineman Thomas Charles | Chief Medical Officer |
Feb 12 '26 |
Buy |
0.83 |
12,132 |
10,033 |
282,818 |
| Brown Deborah Margaret | Director |
Feb 12 '26 |
Buy |
0.85 |
25,000 |
21,240 |
109,851 |
| Hagerman Allison | VP, Product Development |
Feb 12 '26 |
Buy |
0.83 |
10,000 |
8,298 |
115,059 |
| Seizinger Bernd R. | Director |
Feb 11 '26 |
Buy |
0.83 |
60,000 |
49,590 |
526,991 |
| Seizinger Bernd R. | Director |
Feb 12 '26 |
Buy |
0.85 |
40,000 |
33,864 |
566,991 |
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):